{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:32:23Z","timestamp":1740123143411,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s11033-020-05504-5","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T09:02:58Z","timestamp":1590656578000},"page":"4897-4903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment"],"prefix":"10.1007","volume":"47","author":[{"given":"Giorgia","family":"Mazzuccato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"De Bonis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittoria","family":"Carboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Urbani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ettore","family":"Capoluongo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0833-4334","authenticated-orcid":false,"given":"Angelo","family":"Minucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"5504_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin A, Pothuri B, Vergote I et al (2019) PRIMA\/ENGOT-OV26\/GOG-3012 investigators. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381:2391\u20132402. https:\/\/doi.org\/10.1056\/NEJMoa1910962","journal-title":"N Engl J Med"},{"key":"5504_CR2","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Fleming GF, Brady MF et al (2019) Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 381:2403\u20132415. https:\/\/doi.org\/10.1056\/NEJMoa1909707","journal-title":"N Engl J Med"},{"key":"5504_CR3","doi-asserted-by":"crossref","unstructured":"Ray-Coquard I, Pautier P, Pignata S et al (2019) Phase III PAOLA-1\/ENGOT-Ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (oc) treated with platinum-based chemotherapy (pch) plus bev. ESMO; abstract. LBA2.","DOI":"10.1093\/annonc\/mdz394.053"},{"key":"5504_CR4","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/nature06548","volume":"451","author":"SL Edwards","year":"2008","unstructured":"Edwards SL, Brough R, Lord CJ et al (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451:1111\u20131115. https:\/\/doi.org\/10.1038\/nature06548","journal-title":"Nature"},{"key":"5504_CR5","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nature06633","volume":"451","author":"W Sakai","year":"2008","unstructured":"Sakai W, Swisher EM, Karlan BY et al (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451:1116\u20131120. https:\/\/doi.org\/10.1038\/nature06633","journal-title":"Nature"},{"key":"5504_CR6","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1158\/0008-5472.CAN-08-0088","volume":"68","author":"EM Swisher","year":"2008","unstructured":"Swisher EM, Sakai W, Karlan BY et al (2008) Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68:2581\u20132586. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-0088","journal-title":"Cancer Res"},{"key":"5504_CR7","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/ijgc-2019-000757","volume":"29","author":"A Pietragalla","year":"2019","unstructured":"Pietragalla A, Minucci A, Marchetti C et al (2019) Can somatic BRCA2 status solve a case of olaparib monotherapy resistance? Int J Gynecol Cancer 29:1440\u20131445. https:\/\/doi.org\/10.1136\/ijgc-2019-000757","journal-title":"Int J Gynecol Cancer"},{"key":"5504_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/path.4140","volume":"229","author":"LJ Barber","year":"2013","unstructured":"Barber LJ, Sandhu S, Chen L et al (2013) Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol 229:422\u2013429. https:\/\/doi.org\/10.1002\/path.4140","journal-title":"J Pathol"},{"key":"5504_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.yexmp.2019.03.009","volume":"108","author":"M De Bonis","year":"2019","unstructured":"De Bonis M, De Paolis E, Scaglione GL et al (2019) High-resolution melting analysis to screen the ST18 gene functional risk variant for pemphigus vulgaris: the occasion to open a debate on its usefulness in clinical setting. Exp Mol Pathol 108:57\u201363. https:\/\/doi.org\/10.1016\/j.yexmp.2019.03.009","journal-title":"Exp Mol Pathol"},{"issue":"5","key":"5504_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41439-018-0006-x","volume":"8","author":"A Costella","year":"2018","unstructured":"Costella A, De Leo R, Guarino D et al (2018) High-resolution melting analysis coupled with next-generation sequencing as a simple tool for the identification of a novel somatic BRCA2 variant: a case report. Hum Genome Var 8(5):10. https:\/\/doi.org\/10.1038\/s41439-018-0006-x","journal-title":"Hum Genome Var"},{"key":"5504_CR11","doi-asserted-by":"publisher","first-page":"7521","DOI":"10.1038\/srep07521","volume":"4","author":"YP Liu","year":"2014","unstructured":"Liu YP, Wu HY, Yang X et al (2014) Diagnostic accuracy of high resolution melting analysis for detection of KRAS mutations: systematic review and meta-analysis. Sci Rep 4:7521. https:\/\/doi.org\/10.1038\/srep07521","journal-title":"Sci Rep"},{"key":"5504_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1476-4598-8-82","volume":"8","author":"H Do","year":"2009","unstructured":"Do H, Dobrovic A (2009) Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies. Mol Cancer 8:82. https:\/\/doi.org\/10.1186\/1476-4598-8-82","journal-title":"Mol Cancer"},{"key":"5504_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cca.2012.11.023","volume":"416","author":"A Minucci","year":"2013","unstructured":"Minucci A, Canu G, Gentile L et al (2013) (2013) Small amplicons high resolution melting analysis (SA-HRMA) allows successful genotyping of acid phosphatase 1 (ACP1) polymorphisms in the Italian population. Clin Chim Acta 416:86\u201391. https:\/\/doi.org\/10.1016\/j.cca.2012.11.023","journal-title":"Clin Chim Acta"},{"key":"5504_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40291-017-0262-3","volume":"21","author":"A Minucci","year":"2017","unstructured":"Minucci A, De Bonis M, De Paolis E et al (2017) High resolution melting analysis is very useful to identify BRCA1 c.4964_4982del19 (rs80359876) founder calabrian pathogenic variant on peripheral blood and buccal swab DNA. Mol Diagn Ther 21:217\u2013223. https:\/\/doi.org\/10.1007\/s40291-017-0262-3","journal-title":"Mol Diagn Ther"},{"key":"5504_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cca.2017.04.026","volume":"470","author":"A Minucci","year":"2017","unstructured":"Minucci A, De Paolis E, Concolino P et al (2017) Competitive PCR-high resolution melting analysis (C-PCR-HRMA) for large genomic rearrangements (LGRs) detection: a new approach to assess quantitative status of BRCA1 gene in a reference laboratory. Clin Chim Acta 470:83\u201392. https:\/\/doi.org\/10.1016\/j.cca.2017.04.026","journal-title":"Clin Chim Acta"},{"key":"5504_CR16","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s11033-019-05199-3","volume":"47","author":"A Minucci","year":"2020","unstructured":"Minucci A, Mazzuccato G, D'Indinosante M et al (2020) Spliceogenic analysis of BRCA1 c.439T%3eC (rs794727800) variant by high resolution melting analysis. Mol Biol Rep 47:1513\u20131520. https:\/\/doi.org\/10.1007\/s11033-019-05199-3","journal-title":"Mol Biol Rep"},{"key":"5504_CR17","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/annonc\/mdz132","volume":"30","author":"K Nones","year":"2019","unstructured":"Nones K, Johnson J, Newell F et al (2019) Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers. Ann Oncol 30:1071\u20131079. https:\/\/doi.org\/10.1093\/annonc\/mdz132","journal-title":"Ann Oncol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-020-05504-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-020-05504-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-020-05504-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:36:43Z","timestamp":1622162203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-020-05504-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["5504"],"URL":"https:\/\/doi.org\/10.1007\/s11033-020-05504-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"type":"print","value":"0301-4851"},{"type":"electronic","value":"1573-4978"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"10 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declared no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study complied with the Ethical Principles for Medical Research Involving Human Subjects according to the World Medical Association Declaration of Helsinki and was certified by the Committee of the Applicable Institution of the Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was taken from the patient of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}